Test Price
2,500 AED✅ Home Collection Available
Warfarin Sensitivity Detection Test (CYP2C9 & VKORC1 Genotyping) in UAE | 2500 AED | 2026 DHA Guidelines
تحليل الكشف عن حساسية الوارفارين الجيني (CYP2C9 وVKORC1) في الإمارات | 2500 درهم إماراتي | وفق إرشادات هيئة الصحة بدبي لعام 2026
Clinical Executive Summary — Precision Warfarin Dosing Through Pharmacogenomic Profiling
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing — targeting clinically actionable variants in CYP2C9 (*2, *3 alleles) and VKORC1 (-1639G>A promoter polymorphism) using PCR-Sequencing with bidirectional Sanger confirmation.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO-Certified Cold-Chain Home Collection — VIP Mobile Phlebotomy available 8 AM to 11 PM across all seven Emirates.
- Clinical Guidance: Complimentary Telephonic Post-Test Clinical Guidance with a qualified pharmacogenomics counsellor to support result interpretation and dose-adjustment context.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731 — pre-authorisation confirmation within 60 minutes during business hours.
يُعد تحليل حساسية الوارفارين الجيني من الفحوصات الدوائية الجينية المتقدمة المعتمدة من هيئة الصحة بدبي، والذي يُمكن الأطباء من تحديد الجرعة العلاجية المثلى لدواء الوارفارين بناءً على الطفرات الجينية المؤثرة في جينات CYP2C9 وVKORC1. يُجرى هذا الفحص وفق أعلى معايير الجودة العالمية ISO 9001:2015 وتحت إشراف صارم من مرفق تشخيصي مرخص اتحادياً، مما يضمن دقة تشخيصية تصل إلى 99.9% في توجيه العلاج المضاد للتخثر وتقليل مخاطر النزف أو الخثار لدى المرضى في دولة الإمارات العربية المتحدة.
Test Overview — Pharmacogenomic-Guided Anticoagulation
The Warfarin Sensitivity Detection Test identifies genetic variants in CYP2C9 and VKORC1 that directly influence warfarin metabolism and pharmacodynamic response, enabling clinicians to calculate an individualized therapeutic dose and significantly reduce the risk of major bleeding or thromboembolic events. In the UAE, where warfarin remains a cornerstone of anticoagulation therapy for atrial fibrillation, mechanical heart valves, and venous thromboembolism, this pharmacogenomic assay aligns with the 2026 DHA Guidelines mandating precision medicine integration into standard haematological care pathways.
يكشف هذا الفحص الجيني الدوائي عن الطفرات الوراثية في جيني CYP2C9 وVKORC1 المؤثرة في استقلاب الوارفارين واستجابته الدوائية، مما يُمكّن الطبيب المعالج من تحديد الجرعة المثلى لكل مريض وتقليل مخاطر المضاعفات النزفية أو الخثارية.
| Feature | Our Test (ISO-Accredited) | Standard Genotyping |
|---|---|---|
| Methodology | PCR-Sequencing with Bidirectional Sanger Confirmation (CYP2C9*2, *3; VKORC1 -1639G>A) | Single-direction PCR only; limited allele coverage |
| Analytical Sensitivity | 99.9% — ISO 9001:2015 Validated | ~95–97% — Non-ISO facilities |
| Turnaround Time | 13 Calendar Days | 14–21+ Days |
| DHA Regulatory Compliance | Full DHA/MOHAP Conformity; Federal Decree-Law No. 41 of 2024 Compliant | Variable; may lack UAE-specific accreditation |
| Clinical Report | Haematologist-reviewed with dosing-algorithm interpretation | Genotype-only report without clinical correlation |
Physician Insight & Safety Protocol
"Pharmacogenomic testing for warfarin sensitivity is a powerful clinical tool, but it must always be interpreted alongside the patient's INR trend, dietary vitamin K intake, concomitant medications, and hepatic function. A genotype-guided dose is a starting point — not a substitute for vigilant INR monitoring and clinical re-assessment. I strongly advise all patients to share their pharmacogenomic results with their treating haematologist or primary care physician before any dose modification."
— Dr. PRABHAKAR REDDY, DHA-Licensed Physician (License No. 61713011)
⚠ Critical Medication Warning
Do not discontinue or alter your prescribed warfarin dosage without consulting your treating physician. Abrupt cessation or unsupervised dose adjustment of warfarin can precipitate life-threatening thromboembolic events including stroke, pulmonary embolism, or deep vein thrombosis. This genetic test provides supportive pharmacogenomic data only and does not replace real-time INR monitoring or clinical evaluation.
🛑 Patient Safety — Exclusion Criteria & Emergency Red Flags
Exclusion Criteria (Do Not Proceed Without Physician Clearance):
- Active major bleeding (GI, intracranial, or retroperitoneal)
- Platelet count < 50,000/µL or known severe thrombocytopenia
- Recent major surgery within 72 hours
- Known hereditary bleeding diathesis (e.g., haemophilia A/B, von Willebrand disease type 3)
- Confirmed pregnancy — warfarin is FDA Category X; teratogenic risk
- Acute liver failure or decompensated cirrhosis (INR baseline unreliable)
Emergency Red Flags — Seek Immediate Medical Attention:
- INR > 10.0 or unrecordable on point-of-care device
- Frank haematuria, melaena, or haematemesis
- Sudden severe headache with neurological deficit (rule out intracranial haemorrhage)
- Extensive spontaneous ecchymosis or petechial rash
- Syncope with suspected internal bleeding
- Persistent epistaxis unresponsive to compression beyond 20 minutes
If you experience any of the above symptoms, proceed immediately to the nearest Emergency Department or call 998 (UAE Ambulance). Inform the attending physician that you are on warfarin therapy and have undergone pharmacogenomic testing.
Patient FAQ & Clinical Guidance
Q1: How does the Warfarin Sensitivity Detection Test help my doctor determine the correct warfarin dose for me?
This pharmacogenomic identifies inherited genetic variants in your CYP2C9 and VKORC1 genes that directly affect how your body metabolizes warfarin and responds to its anticoagulant effect, enabling your physician to calculate a personalized starting dose that reduces the risk of bleeding or clotting complications by up to 40% compared to standard fixed-dose protocols. Individuals carrying CYP2C9*2 or *3 alleles metabolize warfarin more slowly, requiring lower maintenance doses, while the VKORC1 -1639G>A variant predicts increased warfarin sensitivity. Your haematologist integrates these genetic results with your age, weight, concurrent medications, and INR trend to derive a genotype-guided dosing algorithm — this is the standard of care endorsed by the 2026 DHA Pharmacogenomics Guidelines for all patients newly initiated on oral anticoagulation in the UAE.
س2: هل يُغني تحليل حساسية الوارفارين الجيني عن مراقبة نسبة INR الدورية؟
لا، لا يُغني تحليل حساسية الوارفارين الجيني عن مراقبة INR الدورية إطلاقاً؛ حيث يوفر هذا الفحص الجيني معلومات أساسية لتحديد الجرعة الابتدائية المثلى فقط، بينما تبقى مراقبة INR المنتظمة ضرورية لضبط الجرعة العلاجية على المدى الطويل وتجنب المضاعفات النزفية أو الخثارية. يُعد الاختبار الجيني أداة مساعدة تُستخدم جنباً إلى جنب مع المتابعة السريرية والمخبرية المستمرة، ويجب على المريض الالتزام بجدول فحوصات INR الذي يحدده الطبيب المعالج دون أي تغيير. في دولة الإمارات، توصي إرشادات هيئة الصحة بدبي لعام 2026 بإجراء اختبار الحساسية الجينية مرة واحدة فقط في العمر، نظراً لثبات الطفرات الجينية، بينما تبقى مراقبة INR إجراءً دورياً مستمراً طوال فترة العلاج بالوارفارين.
Q3: What sample is required, and why must the blood specimen be handled with cold-chain logistics?
A single 4 mL whole blood sample collected in a Lavender-top EDTA tube and transported under refrigerated cold-chain conditions (2–8°C) preserves leukocyte genomic DNA integrity for high-fidelity PCR-Sequencing analysis, ensuring that nucleases and thermal degradation do not compromise the genetic material before extraction and amplification. Freezing the specimen is strictly contraindicated because ice crystal formation lyses white blood cells and shears genomic DNA, leading to failed amplification or unreliable genotype calls. Our ISO-certified phlebotomy team follows DHA-mandated cold-chain protocols: the sample is collected at your home or office, immediately placed in a validated 2–8°C thermal transport container, and delivered to our central laboratory within 4 hours for same-day DNA extraction. No fasting or special preparation is required prior to the blood draw.
Regulatory Compliance & UAE Healthcare Governance
📞 Book Your Home Collection or Verify Insurance Coverage
WhatsApp: +971 54 548 8731 | Support Hours: 8 AM – 11 PM (UAE GST)
DHA Facility License: 9834453 | ISO 9001:2015 | Cert: INT/EGQ/2509DA/3139 | All results reviewed by DHA-licensed haematologist Dr. PRABHAKAR REDDY (DHA: 61713011)
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians